The human NB cell lines NB1, SH-SY5Y, CLBGA, and NBL-S and the human lung cancer cell line H3122 (provided by S. Mueller, Evotec, Munich, Germany) were cultured in RPMI 1640 including 2 mM l-glutamine (Gibco) supplemented with 10% fetal bovine serum (Gibco) and penicillin (100 U/ml)–streptomycin (100 μg/ml) (Gibco). Cell lines were maintained at 37°C in a humidified atmosphere at 5% CO2. For SILAC-based quantitative MS, NB1 cells were labeled in SILAC RPMI (PAA Laboratories) supplemented with 10% dialyzed fetal bovine serum (Sigma-Aldrich), 2 mM l-glutamine (Gibco), and penicillin (100 U/ml)–streptomycin (100 μg/ml) (Gibco) for at least 2 weeks to ensure complete incorporation of amino acids. Three cell populations were obtained: one labeled with natural variants of the amino acids (light label; Lys0, Arg0) (Sigma-Aldrich), the second labeled with medium variants of amino acids {L-[2H4]Lys (+4) and L-[13C6]Arg (+6)} (Lys4, Arg6), and the third labeled with heavy variants of the amino acids {L-[13C6,15N2]Lys (+8) and L-[13C6,15N4]Arg (+10)} (Lys8, Arg10). Medium and heavy variants of amino acids were purchased from Cambridge Isotope Laboratories.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.